

LAXMI ORGANIC INDUSTRIES REPORTS Q3FY22 RESULTS

Standalone Operating Revenue of ₹ 8,742 Mn Profit After Tax at ₹ 811 Mn

Mumbai, February 1, 2022: Laxmi Organic Industries Limited (NSE: LXCHEM|BSE:543277|ISIN: INE57600102), one of India's leading specialty chemical manufacturers, has announced its financial results for the quarter ended December 31st, 2021.

Commenting on the strong financial performance Mr. Ravi Goenka, Chairman & Managing Director, said, "I am pleased to provide you with an update on our performance in Q3FY22. Operating revenues for Q3FY22 came in at INR 8,742 million as against INR 3,936 million in Q3FY21. The strong top-line growth was fuelled by a 144% growth in Acetyl Intermediates (AI) and a 113% growth in Specialty Intermediates (SI) on a Y-o-Y basis, respectively.

The strong performance of Acetyl Intermediates (AI) is largely a result of increased realisations and higher volumes. With the anticipated completion of the Yellowstone Chemicals Private Limited (YCPL) merger, we expect these volumes to be sustainable and even increase going forward. The robust performance in Speciality Intermediates (SI) is attributable to ramped up production following the flood restoration and optimising the product portfolio towards higher value-added derivatives. The SI business returned to the growth trajectory of Q1 and continued to see buoyant demand from export markets. This resulted in corresponding growth of 71% and 100% Y-o-Y basis in EBITDA and PAT respectively."

Additionally, he stated, "We remain on track to commercialise our SI CAPEX which will start clocking revenues in Q1FY23."

The fluoro platform remains an exciting opportunity for Laxmi. The Indian and international markets offer a large opportunity for companies like ourselves to play in. The project is facing a delay and cost escalations on account of covid, escalations in the prices of construction materials and logistics challenges. As a matter of strategy, we have decided to launch phase II of the Capex to add incremental capacities simultaneously. The commercial production is expected to start in Q3FY22"

Standalone Financial Highlights for Nine Months Year Ended December 31st, 2021:

- Operating Revenues at ₹ 20,902 Mn in 9M FY22 as compared to ₹ 11,387 Mn in 9M FY21; a growth of 84% Y-o-Y
- EBITDA at ₹ 2,626 Mn in 9M FY22 as compared to ₹ 1,469 Mn in 9M FY21; a growth of 79% Y-o-Y
- EBITDA Margins stood at 13% in 9M FY22, in line with 9M FY21
- Profit After Tax at ₹ 1,901 Mn in 9M FY22 as compared to ₹ 913 Mn in 9M FY21; a growth of 108% Y-o-Y
- EPS for 9M FY22 was 7.21 as compared to 4.06 in 9M FY21

Standalone Financial Highlights for Quarter Ended December 31st, 2021:

- Operating Revenues at ₹ 8,742 Mn in Q3FY22 as compared to ₹ 3,936 Mn in Q3FY21; a growth of 122% Y-o-Y; growth of 66% Q-o-Q
- EBITDA at ₹ 1,019 Mn in Q3 FY22 as compared to ₹ 597 Mn in Q3 FY21; a growth of 71% Y-o-Y and 324% Q-o-Q
- EBITDA margin stood at 12% in Q3 FY22 and contracted by 350 bps Y-o-Y; increase of over 700 bps Q-o-Q
- Profit After Tax at ₹811 Mn in Q3 FY22 as compared to ₹406 Mn in Q3 FY21; a growth of 100% Y-o-Y and around 690% O-o-O
- EPS for Q3FY22 was 3.08 as compared to 1.80 in Q3FY21 and 0.39 in Q2FY22

Consolidated Financial Highlights for Nine Months Year Ended December 31st, 2021:

- Operating Revenues at ₹ 22,043 Mn in 9M FY22 as compared to ₹ 12,489 Mn in 9M FY21; a growth of 76% Y-o-Y
- EBITDA at ₹ 2,948 Mn in 9M FY22 as compared to ₹ 1,530 Mn in 9M FY21; a growth of 93% Y-o-Y
- EBITDA Margins stood at 13% in 9M FY22 as compared to 12% in 9M FY21
- Profit After Tax at ₹ 1,990 Mn in 9M FY22 as compared to ₹ 907 Mn in 9M FY21; a growth of 119% Y-o-Y
- EPS for 9M FY22 was 7.55 as compared to 4.03 in 9M FY21

Consolidated Financial Highlights for Quarter Ended December 31st, 2021:

- Operating Revenues at ₹ 8,599 Mn in Q3FY22 as compared to ₹ 4,355 Mn in Q3FY21; a growth of 97% Y-o-Y; growth of 41% Q-o-Q
- EBITDA at ₹ 1,187 Mn in Q3FY22 as compared to ₹ 677 Mn in Q3FY21; a growth of 75% Y-o-Y and a growth of 284% O-o-O
- EBITDA Margins stood at 14% in Q3FY22 and contracted by 173 bps Y-o-Y; and expanded by 872 bps Q-o-Q
- Profit After Tax at ₹821 Mn in Q3FY22 as compared to ₹452 Mn in Q3FY21; a growth of 82% Y-o-Y and of 464% Q-o-Q
- EPS for Q3FY22 was 3.11 as compared to 2.01 in Q3FY21 and 0.55 in Q2FY22



About Laxmi Organic Industries Ltd. (LXCHEM):

Laxmi Organic Industries Ltd (LXCHEM) is a leading manufacturer of Acetyl Intermediates and Specialty Intermediates with almost three decades of experience in large scale manufacturing of chemicals. It is currently among the largest manufacturers of ethyl acetate in India with a market share of approximately 30% of the Indian ethyl acetate market. It is the only manufacturer of diketene derivatives in India with a market share of approximately 55 % of the Indian diketene derivatives market. LXCHEM's products are currently divided into two broad categories, namely the Acetyl Intermediates and the Specialty Intermediates. The Acetyl Intermediates include ethyl acetate, acetaldehyde, fuel-grade ethanol and other proprietary solvents, while the Specialty Intermediates comprises of ketene, diketene derivatives namely esters, acetic anhydride, amides, arylides and other chemicals. Its products find application in various high-growth industries, including pharmaceuticals, agrochemicals, dyes & pigments, inks & coatings, paints, printing & packaging, flavours & fragrances, adhesives and other industrial applications. It also propose to diversify into manufacturing of specialty fluorochemicals to which end, it has recently acquired assets including plant & machinery, design and operating paperwork, REACH registrations and patents of Miteni, a manufacturer of organic fluorospecialties and electrochemical fluorination.

For more information, please visit: https://www.laxmi.com/

FOR FURTHER DETAILS PLEASE GET IN TOUCH WITH:

LAXMI ORGANIC INDUSTRIES
Email: investors@laxmi.com

DIWAKAR PINGLE / KANAV KHANNA

CHRISTENSEN ADVISORY

Email: dpingle@christensenir.com kkhanna@christensenir.com